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ABSTRACT
Neuropathic pain develops when the
somatosensory nervous system is affected by a
lesion or disease. Diagnostic tests aimed at
assessing somatosensory afferent pathway dam-
age are therefore useful for diagnosing neuro-
pathic pain. Neuropathic pain manifests with a
range of different symptoms such as ongoing
burning pain, squeezing or pressure pain, parox-
ysmal electric shock-like sensations, stabbing
pain, or mechanical dynamic allodynia. The var-
ious types of neuropathic pain are associatedwith
different underlying nerve fiber abnormalities.
This article summarizes the available methods of
somatosensory afferent pathway assessment and
discusses the potential pathophysiology under-
lying the most representative neuropathic pain
types, i.e., ongoing burning pain, paroxysmal
pain, and mechanical dynamic allodynia.
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INTRODUCTION
Neuropathic pain is due to a lesion or disease of
the somatosensory nervous system [1]. Besides
clinical examination, diagnostic tests assessing
non-nociceptive and nociceptive afferent path-
ways are useful in patients with suspected neu-
ropathic pain, as they provide definite evidence
of somatosensory nervous system damage. Dif-
ferent diseases of the peripheral and central
nervous system may cause neuropathic pain
(e.g.. diabetic neuropathy, postherpetic neural-
gia, multiple sclerosis) [1, 2].
Neuropathic pain manifests as a range of dif-
ferent symptoms, including ongoing burning
pain, pain similar to squeezing or pressure,
paroxysmal electric shock-like sensations or
stabbing pain, and mechanical dynamic allody-
nia [1]. This article summarizes the available
methods for assessing neuropathic pain and dis-
cusses the potential pathophysiology underlying
various neuropathic pain phenotypes.
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PAIN ASSESSMENT
There are several available methods for the assess-
ment of somatosensory afferent pathways in
patients with suspected neuropathic pain (Fig. 1).
Quantitative Sensory Testing
Quantitative sensory testing (QST) is a psy-
chophysical technique that measures percep-
tion in response to controlled skin stimuli of
ascending and descending orders of magnitude
in patients with suspected neuropathic pain [3].
QST enables clinicians to assess small-fiber
neuropathies (SFNs), which are often misdiag-
nosed with clinical examination and not
apparent on standard nerve-conduction studies.
QST measures the perception of mechanical,
thermal, and painful stimuli, and is particularly
suited to assess mechanical and thermal allo-
dynia and hyperalgesia. However, as sensory
abnormalities are often reported in non-neuro-
pathic pain, QST is insufficient to determine
differential diagnoses [3].
Neurophysiological Techniques
Neurophysiological techniques include nerve
conduction studies and measurement of
somatosensory-evoked potentials (SEPs),
trigeminal reflexes, laser-evoked potentials
(LEPs), contact-heat-evoked potentials (CHEPs),
and microneurography [3, 4]. These techniques
assess large non-nociceptive and small noci-
ceptive afferent fibers, and are therefore useful
in the diagnosis of central nervous system (CNS)
and peripheral nervous system (PNS) diseases.
Standard nerve conduction studies and SEPs
are considered to be first-line techniques in
patients with suspected neuropathic pain [4].
The standard nerve conduction study is the
reference standard technique for a definite
diagnosis of peripheral neuropathy. SEPs are
used to assess patients with CNS disorders, such
as multiple sclerosis and spinal cord injury [5].
Trigeminal reflexes are considered the best
neurophysiological tool for investigating
patients with trigeminal disease. They consist of
different reflex responses. The most widely used
trigeminal reflex responses are the blink reflex
and the masseter inhibitory reflex; these
responses allow for assessing the three trigemi-
nal nerve divisions [6]. Although nerve con-
duction studies, somatosensory evoked
potentials, and trigeminal reflexes are widely
Fig. 1 Laboratory tests for diagnosing neuropathic pain
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used for assessing somatosensory afferent path-
way damage, they are responses mediated by
non-nociceptive fibers, and thus they do not
provide any information on the nociceptive
system.
LEPs and CHEPs are widely used for investi-
gating the nociceptive system. Laser-generated
heat pulses and contact heat stimuli selectively
activate Ad and C mechano-thermal nocicep-
tors, evoking scalp potentials associated with
Ad fiber activation [3–5].
Microneurography is a minimally invasive
method for recording action potential from
nociceptive C axons [3]. However, this tech-
nique is time consuming, has limited availabil-
ity, and requires an expert investigator and a
cooperative patient; therefore, its use in routine
practice is not yet well established.
Skin Biopsy
Punch skin biopsies with immunostaining
allow for visualization and assessment of
intraepidermal nerve fiber (IENF) density [3].
Biopsies are analyzed by bright-field immuno-
histochemistry or immunofluorescence, typi-
cally with antibodies against the protein gene
product 9.5, a nonspecific panaxonal marker
[7, 8]. Decreased IENF density is indicative of
SFN, and is a reliable method of establishing
this diagnosis [7]. Biopsies are commonly used
to investigate small-fiber involvement in
patients with diabetic neuropathy, or neuropa-
thy of infectious or inflammatory etiology
[7, 8]. However, the relationship between skin
biopsy data and neuropathic pain is complex;
IENF density may be associated with the exis-
tence of neuropathic pain, but does not corre-
late with pain intensity [9].
TYPES OF NEUROPATHIC PAIN
Ongoing Burning Pain
Ongoing burning pain is one of the most rep-
resentative types of neuropathic pain. In
patients with distal symmetrical peripheral
neuropathy, the burning pain results from
hyperexcitability of irritable nociceptors or
regenerating nerve sprouts [1]. Microneurogra-
phy has shown that, in patients with
length-dependent painful neuropathy (e.g.,
postherpetic neuralgia or radiculopathy), the
ongoing pain is caused by abnormal sponta-
neous C fiber activity [10, 11]. In other neuro-
pathic pain conditions, the cause is anatomical
denervation in which a primary lesion affects
the neuronal cell body or postganglionic axon
exposing the postsynaptic membrane of the
second-order neuron to local transmitters,
consequently causing spontaneous firing [1].
This process, called ‘‘denervation supersensitiv-
ity’’, is associated with burning pain [12].
Paroxysmal Pain
Paroxysmal pain is often described as a shoot-
ing, electric-shock like or stabbing sensation.
Previous studies have associated paroxysmal
electric shock-like with non-nociceptive
Ab fiber abnormalities in patients with pos-
therpetic neuralgia or carpal tunnel syndrome
[13, 14]. In these patients, neurophysiological
test findings suggest that the paroxysmal pain
may originate from focal demyelination of Ab
fibers [13, 14].
In trigeminal neuralgia, the most represen-
tative neuropathic pain condition manifesting
with paroxysmal pain, focal compression by
aberrant vessels or benign tumors mechanically
damages large myelinated fibers and causes
demyelination [15, 16]. Ab fiber demyelination
increases the susceptibility of neurons to ecto-
pic excitation and high-frequency discharges,
which leads to typical paroxysmal pain [15, 16].
Allodynia
Allodynia is the experience of pain from a
non-painful stimulation of the skin, such as
light touch; this is in contrast to hyperalgesia,
which is experiencing more intense pain than
would be expected from stimuli that normally
cause pain. Dynamic mechanical allodynia (i.e.,
elicited by light, moving, tactile stimuli) devel-
ops when a pain pathway lesion causes changes
in the reactivity of central nociceptive neurons,
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such that they respond to low-threshold Ab
afferent fibers [1, 12]. Examples of dynamic
mechanical allodynia include pain caused by
skin contact with clothing in patients with
postherpetic neuralgia, or contact between feet
and bed sheets in patients with peripheral
neuropathy. Dynamic mechanical allodynia
therefore appears to be caused by Ab fiber
abnormalities [1]. Selective blockade of A fiber
signaling in patients with neuropathic pain
abolishes allodynia, but has no effect on burn-
ing pain, which is mediated by C fiber afferents
[17]. The slow conduction velocity through Ad
and C fibers means these fibers are unlikely to
contribute to the initial explosive onset of
dynamic allodynia, but their hyperexcitability
may modulate and maintain the ongoing
after-sensations and play a role in the observed
CNS changes [1]. This hypothesis is supported
by studies showing that allodynia is relieved by
topical lidocaine in patients with postherpetic
neuralgia [18, 19].
Most investigators consider allodynia to be a
CNS phenomenon occurring as a result of cen-
tral sensitization, but others propose that allo-
dynia is caused by peripheral sensitization.
Indirect support for the latter hypothesis comes
from studies using QST and LEPs. QST testing
shows that thermal-pain sensation is preserved
in many patients with postherpetic neuralgia
who experience allodynia [1]. A previous study
showed that patients with painful neuropathy
and allodynia have partially preserved LEPs
compared with patients with painful neuropa-
thy and no allodynia [1]. However, the most
convincing evidence that sensitized peripheral
nociceptors are the primary determinant of
allodynia comes from microneurographic stud-
ies. These studies showed that allodynia occurs
secondary to abnormal firing of C nociceptors
in response to light mechanical stimulation
[10].
CONCLUSION
Diagnostic tests reliably provide evidence of
somatosensory afferent pathway damage, thus
supporting the diagnosis of neuropathic pain.
Neuropathic pain manifests with different
symptoms. Evidence suggests that each symp-
tom is mediated by a distinct mechanism. This
has implications for treatment. Pharmacologi-
cal treatment should be targeted to the specific
mechanism.
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